

5,11-DIAZADITWISTANE

Jan ten Broeke, Alan W. Douglas, Matthew  
A. Kozlowski and Edward J. J. Grabowski\*


Merck Sharp & Dohme Research Laboratories  
Division of Merck & Co., Inc.  
Rahway, New Jersey 07065

(Received in USA 22 September 1977; received in UK for publication 14 October 1977)

Recently we reported the synthesis of 2,9-dicyano-5,11-dimethyl-5,11-diazatetracyclo[6.2.2.0<sup>2,7</sup>.0<sup>4,9</sup>]dodecane (1), the first analog of the then unknown diazaditwistane series.<sup>1</sup> In a subsequent publication the conversion of 1 to a series of potent analgesics was discussed.<sup>2</sup> As part of our continuing study of 1 and its analogs, we wish to report its conversion to the parent diazaditwistane, 5,11-diazatetracyclo[6.2.2.0<sup>2,7</sup>.0<sup>4,9</sup>]dodecane (7). In the recent literature the chemistry of simpler analogs, such as ditwistane and azatwistane, has been discussed.<sup>3,4a,b</sup>

Treatment of 1 with excess ethyl chloroformate at reflux resulted in facile demethylation and formation of 2 (72% yield, m.p. 193-195°C).<sup>5</sup> Controlled hydrolysis of 2 with 6N HCl at reflux for 6 hrs. afforded diacid 3 (81%, m.p. 302-304°C, decomp.). Decarboxylation of 3 using Br<sub>2</sub>/HgO<sup>6</sup> afforded dibromo-bis-urethane 4 (37% m.p. 194-196.5°C) along with bromoacid 5 (21%, m.p. 242-245°C decomp.). Reduction of 4 with tri-n-butyltin hydride and ethyl acetate at reflux, followed by hydrolysis of the mixture, without isolation of 6, in 48% aqueous HBr afforded 7 as its dihydrobromide salt in 45% overall yield. Alternatively, decarboxylation of 3 with lead tetraacetate in dioxane afforded 6 directly, which when subjected to the HBr hydrolysis afforded 7 in 50% overall yield as its dihydrobromide salt (m.p. > 300).<sup>5</sup> Neutralization of the salt with NaOH, followed by freeze drying and sublimation of the resulting solid, afforded 7 as its free base (m.p. 224-226°C). As characteristic of all compounds in this series, 7 displayed an intense molecular ion (m/e 164), a base peak corresponding to fragmentation to its pyridinium analog, which for 7 corresponds to protonated pyridine (m/e 80).

The NMR data for 7, obtained with a Varian XL-100 spectrometer, are summarized in Table I. The C<sub>2</sub> axis of symmetry, already noted for 1 and its biologically active analogs<sup>1,2</sup>, is readily apparent from these data. Further studies with this unique system are continuing and will be reported in the future.



1.  $R_2 = R_9 = \text{CN}$ ;  $R_5 = R_{11} = \text{CH}_3$
2.  $R_2 = R_9 = \text{CN}$ ;  $R_5 = R_{11} = \text{COOC}_2\text{H}_5$
3.  $R_2 = R_9 = \text{COOH}$ ;  $R_5 = R_{11} = \text{COOC}_2\text{H}_5$
4.  $R_2 = R_9 = \text{Br}$ ;  $R_5 = R_{11} = \text{COOC}_2\text{H}_5$
5.  $R_2 = \text{Br}$ ;  $R_9 = \text{COOH}$ ;  $R_5 = R_{11} = \text{COOC}_2\text{H}_5$
6.  $R_2 = R_9 = \text{H}$ ;  $R_5 = R_{11} = \text{COOC}_2\text{H}_5$
7.  $R_2 = R_5 = R_9 = R_{11} = \text{H}$

TABLE I

NMR Data for 5,11-Diazaditwistane·2HBr

 $^1\text{H}$ NMR (9.5 mg/0.5 cc  $\text{D}_2\text{O}$ ,  $(\text{CH}_3)_4\text{N}^+\text{Br}^-$  reference, 3.33 ppm)

$\delta_{\text{H}}$	Mult.	# H's (relative)	Assignment
2.08	t ( $J = 2.9$ hz)	4	3,10- $\text{CH}_2$ 's
2.27-2.37	m	2	7,8- $\text{CH}$ 's
2.65-2.82	m*	2	2,9- $\text{CH}$ 's
3.44-3.77	m**	4	6,12- $\text{CH}_2$ 's
3.89-3.98	m***	2	1,4- $\text{CH}$ 's

\*Appears as t,  $J = 6.3$  hz, when 3,10- $\text{CH}_2$ 's decoupled.\*\* AB part of ABX pattern;  $J_{\text{AB}} = 12.7$  hz,  $|J_{\text{AX}}| + |J_{\text{BX}}| = 4.7$  hz. Unaffected by decoupling of 3,10- $\text{CH}_2$ 's.\*\*\*Appears as d,  $J = 6.1$  hz when 3,10- $\text{CH}_3$ 's decoupled. $^{13}\text{C}$ NMR (100 mg/0.5 cc  $\text{D}_2\text{O}$ , dioxane reference, 67.4 ppm)

$\delta_{\text{C}}$	Off-resonance Multiplicity	$^1J_{13\text{CH}}$ (hz)	Assignment
21.7	t	134	$\text{C}_{3,10}$
26.9	d	$\sim 147$	$\text{C}_{2,9}$
27.7	d	138	$\text{C}_{7,8}$
42.2	t	148	$\text{C}_{6,12}$
48.4	d	157	$\text{C}_{1,4}$

References

1. J. ten Broeke, A. W. Douglas and E. J. J. Grabowski, *J. Org. Chem.*, **41**, 3159 (1976).
2. M. H. Fisher, E. J. J. Grabowski, A. A. Patchett, J. ten Broeke, L. M. Flataker, V. J. Lotti and F. M. Robinson, *J. Med. Chem.*, **20**, 63 (1977).
3. K.-I. Hirao, T. Iwakuma, M. Taniguchi, E. Abe, O. Yonemitsu, T. Date and K. Kotera, *J. Chem. Soc., Chem. Comm.*, 691 (1974).
- 4a. P. Deslongchamps, L. Ruestet, and S. Dube, *Can. J. Chem.*, **53**, 3613 (1975).
- 4b. R. W. Lockhart, K. Hanaya, W. B. Einstein, and Y. L. Chow, *J. Chem. Soc., Chem. Comm.*, 344 (1975).
5. All new compounds afforded satisfactory spectral and analytical data.
6. W. Della and H. K. Patney, *Synthesis*, 251 (1976).